vs
Side-by-side financial comparison of Alignment Healthcare, Inc. (ALHC) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Alignment Healthcare, Inc. is the larger business by last-quarter revenue ($1.2B vs $783.7M, roughly 1.6× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs 0.9%, a 12.0% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs -74.7%). Over the past eight quarters, Alignment Healthcare, Inc.'s revenue compounded faster (34.6% CAGR vs 33.2%).
Alignment Healthcare, Inc. is a U.S.-based healthcare provider offering Medicare Advantage plans for seniors. It adopts a value-based care model, partnering with local providers to deliver personalized coordinated medical services, prescription drug coverage and supplemental benefits to members across multiple U.S. states.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
ALHC vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $783.7M |
| Net Profit | $11.4M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | 0.9% | 13.0% |
| Revenue YoY | -74.7% | 31.2% |
| Net Profit YoY | — | 0.9% |
| EPS (diluted) | — | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.0B | $783.7M | ||
| Q3 25 | $993.7M | $706.3M | ||
| Q2 25 | $1.0B | $649.1M | ||
| Q1 25 | $926.9M | $569.0M | ||
| Q4 24 | $701.2M | $597.5M | ||
| Q3 24 | $692.4M | $543.9M | ||
| Q2 24 | $681.3M | $488.5M |
| Q1 26 | $11.4M | — | ||
| Q4 25 | $-11.0M | $101.6M | ||
| Q3 25 | $3.7M | $87.6M | ||
| Q2 25 | $15.7M | $22.5M | ||
| Q1 25 | $-9.1M | $35.4M | ||
| Q4 24 | $-31.1M | $100.7M | ||
| Q3 24 | $-26.4M | $77.5M | ||
| Q2 24 | $-24.0M | $188.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% |
| Q1 26 | — | — | ||
| Q4 25 | -1.0% | 18.7% | ||
| Q3 25 | 0.8% | 16.7% | ||
| Q2 25 | 2.2% | 18.7% | ||
| Q1 25 | -0.6% | 15.6% | ||
| Q4 24 | -3.2% | 18.3% | ||
| Q3 24 | -2.8% | 16.2% | ||
| Q2 24 | -2.7% | 11.2% |
| Q1 26 | 0.9% | — | ||
| Q4 25 | -1.1% | 13.0% | ||
| Q3 25 | 0.4% | 12.4% | ||
| Q2 25 | 1.5% | 3.5% | ||
| Q1 25 | -1.0% | 6.2% | ||
| Q4 24 | -4.4% | 16.9% | ||
| Q3 24 | -3.8% | 14.2% | ||
| Q2 24 | -3.5% | 38.6% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.04 | $1.42 | ||
| Q3 25 | $0.02 | $1.24 | ||
| Q2 25 | $0.07 | $0.32 | ||
| Q1 25 | $-0.05 | $0.50 | ||
| Q4 24 | $-0.15 | $1.38 | ||
| Q3 24 | $-0.14 | $1.08 | ||
| Q2 24 | $-0.13 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $705.6M | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $206.9M | $1.5B |
| Total Assets | $1.3B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $705.6M | — | ||
| Q4 25 | $604.2M | — | ||
| Q3 25 | $644.1M | — | ||
| Q2 25 | $503.8M | — | ||
| Q1 25 | $479.5M | — | ||
| Q4 24 | $470.6M | — | ||
| Q3 24 | $381.0M | — | ||
| Q2 24 | $363.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $323.2M | $930.8M | ||
| Q3 25 | $322.7M | $934.9M | ||
| Q2 25 | $322.3M | $939.0M | ||
| Q1 25 | $321.9M | $1.6B | ||
| Q4 24 | $321.4M | $1.3B | ||
| Q3 24 | $212.0M | $1.4B | ||
| Q2 24 | $211.7M | $1.4B |
| Q1 26 | $206.9M | — | ||
| Q4 25 | $179.3M | $1.5B | ||
| Q3 25 | $161.9M | $1.4B | ||
| Q2 25 | $141.0M | $1.5B | ||
| Q1 25 | $108.1M | $1.3B | ||
| Q4 24 | $99.9M | $1.2B | ||
| Q3 24 | $114.5M | $1.1B | ||
| Q2 24 | $123.7M | $998.4M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.1B | $3.2B | ||
| Q3 25 | $1.1B | $3.0B | ||
| Q2 25 | $1.0B | $3.5B | ||
| Q1 25 | $895.6M | $3.5B | ||
| Q4 24 | $782.1M | $3.1B | ||
| Q3 24 | $692.3M | $3.0B | ||
| Q2 24 | $716.3M | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | 1.80× | 0.61× | ||
| Q3 25 | 1.99× | 0.68× | ||
| Q2 25 | 2.29× | 0.64× | ||
| Q1 25 | 2.98× | 1.21× | ||
| Q4 24 | 3.22× | 1.07× | ||
| Q3 24 | 1.85× | 1.21× | ||
| Q2 24 | 1.71× | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $128.7M | $183.3M |
| Free Cash FlowOCF − Capex | — | $48.2M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | — | 17.2% |
| Cash ConversionOCF / Net Profit | 11.27× | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | — | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $128.7M | — | ||
| Q4 25 | $-50.4M | $183.3M | ||
| Q3 25 | $144.6M | $125.7M | ||
| Q2 25 | $29.1M | $196.5M | ||
| Q1 25 | $16.6M | $63.8M | ||
| Q4 24 | $-8.7M | $147.7M | ||
| Q3 24 | $26.2M | $98.5M | ||
| Q2 24 | $23.5M | $96.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-55.4M | $48.2M | ||
| Q3 25 | $139.1M | $100.1M | ||
| Q2 25 | $21.1M | $177.9M | ||
| Q1 25 | $8.4M | $51.5M | ||
| Q4 24 | $-18.0M | $94.1M | ||
| Q3 24 | $16.9M | $71.8M | ||
| Q2 24 | $11.8M | $74.0M |
| Q1 26 | — | — | ||
| Q4 25 | -5.5% | 6.2% | ||
| Q3 25 | 14.0% | 14.2% | ||
| Q2 25 | 2.1% | 27.4% | ||
| Q1 25 | 0.9% | 9.1% | ||
| Q4 24 | -2.6% | 15.7% | ||
| Q3 24 | 2.4% | 13.2% | ||
| Q2 24 | 1.7% | 15.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 17.2% | ||
| Q3 25 | 0.6% | 3.6% | ||
| Q2 25 | 0.8% | 2.9% | ||
| Q1 25 | 0.9% | 2.2% | ||
| Q4 24 | 1.3% | 9.0% | ||
| Q3 24 | 1.3% | 4.9% | ||
| Q2 24 | 1.7% | 4.6% |
| Q1 26 | 11.27× | — | ||
| Q4 25 | — | 1.80× | ||
| Q3 25 | 38.77× | 1.43× | ||
| Q2 25 | 1.86× | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALHC
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
